8-K: Cingulate Files CTx-1301 NDA, Reports Q2 Loss

Cingulate Inc. submitted its New Drug Application for lead ADHD asset CTx-1301 to the FDA and reported increased net loss and expenses for the second quarter of 2025.

Summary

• Submitted New Drug Application (NDA) for CTx-1301 to the FDA on July 31, 2025.
• Anticipates FDA decision on NDA acceptance in Q4 2025, with a potential PDUFA date in mid-2026.
• Reported a net loss of $4.8 million for the three months ended June 30, 2025, compared to $3.2 million for the same period in 2024.
• Research and development expenses increased by 43.6% to $2.7 million, and general and administrative expenses increased by 47.1% to $1.9 million for the quarter.
• Cash and cash equivalents were $8.9 million as of June 30, 2025, a $3.3 million decrease from December 31, 2024.
• Working capital decreased by $4.2 million to $3.5 million as of June 30, 2025, from $7.7 million at December 31, 2024.
• Entered into a purchase agreement with Lincoln Park Capital on July 21, 2025, for the potential sale of up to $25.0 million of common stock over 36 months.
• Expects current cash to fund operations into late 2025 and will need to raise approximately $1.5 million to advance commercialization efforts into early 2026.

Sentiment

Score: 5

Explanation: The filing presents a mixed bag. The significant progress with the NDA submission and positive clinical trial results are strong positives, indicating advancement towards commercialization. However, the financial results show increased losses and declining cash/working capital, coupled with an explicit need for additional capital in the near term, which introduces financial risk and potential dilution. The capital raise agreement provides a mechanism but doesn't guarantee the needed funds without dilution.

Positives

• Submission of the New Drug Application (NDA) for CTx-1301 to the FDA marks a pivotal milestone in the company's progression towards commercialization.
• Positive top-line results from the high dose (50mg) fed/fast study of CTx-1301 demonstrated the drug can be taken with or without food, offering patient flexibility.
• Results from the Phase 3 pediatric study of CTx-1301 showed marked improvement of ADHD symptoms at week five, indicating potential product benefits.
• The agreement with Lincoln Park Capital provides access to up to $25.0 million in capital over 36 months, offering financial flexibility for future needs.
• CTx-1301 is designed to address major limitations of current ADHD therapies by providing fast onset, entire active-day efficacy, and a smooth pharmacokinetic profile with a single dose.

Negatives

• Net loss increased to $4.8 million for Q2 2025, up from $3.2 million in Q2 2024, primarily due to increased operating expenses.
• Research and development expenses rose by 43.6% to $2.7 million in Q2 2025, driven by NDA submission activities.
• General and administrative expenses increased by 47.1% to $1.9 million in Q2 2025, mainly due to higher legal and financial advisory fees.
• Cash and cash equivalents decreased by $3.3 million from December 31, 2024, to $8.9 million as of June 30, 2025.
• Working capital decreased by $4.2 million from December 31, 2024, to $3.5 million as of June 30, 2025.
• Current cash is expected to satisfy capital needs only into late 2025, requiring an additional $1.5 million to advance commercialization efforts into early 2026.

Risks

• Uncertainty regarding FDA acceptance of the NDA for CTx-1301 and the timing of potential approval, which could impact commercialization timelines.
• Need to raise approximately $1.5 million of additional capital to fund commercialization efforts into early 2026, which may be subject to market conditions and dilution.
• Reliance on the proprietary Precision Timed Release (PTR) drug delivery platform technology, which may face challenges in broader application or competitive landscapes.
• Competition within the ADHD treatment market, which includes established stimulant therapies and other extended-release products.
• The ability to successfully commercialize CTx-1301 pending FDA approval, including market adoption and reimbursement.

Future Outlook

Cingulate anticipates an FDA decision regarding the acceptance of its CTx-1301 NDA in Q4 2025, with a potential PDUFA date in mid-2026. The company expects its current cash to fund operations into late 2025 and plans to raise approximately $1.5 million to advance pre-commercialization efforts for CTx-1301 into early 2026, pending FDA approval.

Management Comments

• "Submission of the NDA to the FDA for lead asset CTx-1301 marked a pivotal moment in Cingulate's progression, reflecting years of dedication to developing a truly differentiated ADHD treatment through the Precision Timed Release platform." Jay Roberts, Executive Chairman.
• "The recently executed agreement with Lincoln Park Capital allows management to be opportunistic in its capital needs as we prioritize pre-commercial activities in anticipation of the launch of lead asset CTx-1301 in mid-2026, pending FDA approval." Jay Roberts, Executive Chairman.

Industry Context

The ADHD market is substantial and growing, with over 20 million diagnosed patients in the U.S., including a rapidly expanding adult segment. Cingulate's CTx-1301, utilizing its Precision Timed Release (PTR) platform, aims to address key limitations of existing stimulant therapies by offering a single-dose, extended-release solution for entire active-day efficacy. This positions Cingulate to potentially capture market share by improving patient adherence and outcomes in a competitive landscape dominated by established stimulant and extended-release products.

Stakeholder Impact

• Shareholders: Potential for significant value creation if CTx-1301 gains FDA approval and market adoption, but also risk of dilution from future capital raises and increased losses.
• Patients: Potential for an improved ADHD treatment option with CTx-1301's extended-release profile, addressing current therapy limitations.
• Employees: Continued focus on product development and commercialization, potentially leading to growth opportunities if CTx-1301 is successful.
• Creditors: Financial performance indicates increased burn rate, but the Lincoln Park Capital agreement provides a potential source of funding.

Next Steps

• FDA decision regarding NDA acceptance for CTx-1301 in Q4 2025.
• Potential PDUFA date for CTx-1301 in mid-2026.
• Advance pre-commercial activities for CTx-1301 in anticipation of launch.
• Raise approximately $1.5 million of additional capital to fund commercialization efforts into early 2026.
• Potentially utilize the purchase agreement with Lincoln Park Capital for up to $25.0 million in common stock over 36 months.
• Identify and develop additional product candidates in other therapeutic areas using the PTR technology.

Key Dates

Recommendation

While the submission of the CTx-1301 NDA is a significant positive milestone, indicating progress towards commercialization and validating the company's platform, the deteriorating financial position with increased losses and declining cash reserves is a concern. The need for additional capital in the near term, despite the Lincoln Park Capital agreement, suggests potential future dilution. The stock is a 'hold' as the positive clinical and regulatory progress is balanced by the financial challenges and the inherent risks associated with FDA approval and commercial launch in the highly competitive pharmaceutical market. Investors should monitor FDA decisions and the company's capital management closely.

Keywords

ADHD, CTx-1301, NDA, FDA, Biopharmaceutical, Drug Delivery, Precision Timed Release, Dexmethylphenidate, Clinical Trials, Capital Raise, Cingulate